Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?

November 13, 2017 - By Migdalia James

 Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?
Investors sentiment decreased to 0.54 in Q2 2017. Its down 0.61, from 1.15 in 2017Q1. It fall, as 13 investors sold Argos Therapeutics Inc shares while 15 reduced holdings. 9 funds opened positions while 6 raised stakes. 1.91 million shares or 42.00% less from 3.30 million shares in 2017Q1 were reported.
Creative Planning has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Manufacturers Life The owns 1,050 shares for 0% of their portfolio. Moreover, State Street Corporation has 0% invested in Argos Therapeutics Inc (NASDAQ:ARGS). 129,046 were reported by Geode Ltd Liability Company. Susquehanna Group Limited Liability Partnership accumulated 31,271 shares. Captrust Fincl Advisors has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Hightower Advsrs Ltd Company invested in 0% or 32,071 shares. Tower Cap Lc (Trc) holds 4,914 shares or 0% of its portfolio. Savings Bank Of America De has invested 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS). Gp One Trading Ltd Partnership has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Element Mngmt Ltd Liability Company reported 82,808 shares. Bnp Paribas Arbitrage owns 0% invested in Argos Therapeutics Inc (NASDAQ:ARGS) for 4 shares. Goldman Sachs invested in 0% or 110,181 shares. Citadel Advsrs Lc accumulated 17,989 shares. Lmr Llp owns 45,017 shares or 0% of their US portfolio.

Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Argos Therapeutics has $18 highest and $12 lowest target. $14.25’s average target is 8089.66% above currents $0.174 stock price. Argos Therapeutics had 6 analyst reports since November 16, 2015 according to SRatingsIntel. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) has “Outperform” rating given on Monday, November 16 by FBR Capital. JMP Securities maintained the shares of ARGS in report on Wednesday, March 9 with “Market Outperform” rating. Roth Capital maintained it with “Buy” rating and $18 target in Tuesday, April 19 report. FBR Capital maintained Argos Therapeutics Inc (NASDAQ:ARGS) rating on Thursday, August 11. FBR Capital has “Outperform” rating and $13 target. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) has “Hold” rating given on Thursday, September 21 by Needham. The rating was maintained by Needham on Tuesday, November 17 with “Buy”. Below is a list of Argos Therapeutics Inc (NASDAQ:ARGS) latest ratings and price target changes.

21/09/2017 Broker: Needham Rating: Hold Maintain

The stock decreased 6.00% or $0.011 during the last trading session, reaching $0.174. About 5,501 shares traded. Argos Therapeutics Inc (NASDAQ:ARGS) has declined 92.57% since November 13, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $9.56 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

More important recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Streetinsider.com which released: “Argos Therapeutics (ARGS) Receives Milestone Payment from Lummy” on November 06, 2017, also Globenewswire.com published article titled: “Argos Therapeutics to Report Third Quarter 2017 Financial Results and …”, Globenewswire.com published: “Argos Reports Third Quarter 2017 Financial Results and Operational Highlights” on November 09, 2017. More interesting news about Argos Therapeutics Inc (NASDAQ:ARGS) was released by: Streetinsider.com and their article: “Argos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 …” with publication date: November 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.